Hope for rare fat disorder: expanded access to metreleptin offered
NCT ID NCT02404896
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This expanded access program provides metreleptin (MyaLept) to patients with familial partial lipodystrophy who also have diabetes or very high triglycerides. Metreleptin is already approved for generalized lipodystrophy, but this program aims to help those with the partial form. Participants receive open-label treatment, and the goal is to manage blood sugar and fat levels.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
metreleptin (MyaLept)
What this could lead to
If successful, this could provide ongoing disease control for patients with partial lipodystrophy who have diabetes or high triglycerides.
What could go wrong
This is an expanded access program, not a formal trial, so results are limited. Metreleptin is already approved for generalized lipodystrophy, but its benefits in partial lipodystrophy are less certain and may not work for everyone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FAMILIAL PARTIAL LIPODYSTROPHY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Michigan
AVAILABLEAnn Arbor, Michigan, 48105, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact